Granisetron

Generic Name: Granisetron

Brand Names: Sancuso, Sustol

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₄N_₄O

CAS Number: 109889-09-0

Unique Ingredient Identifier: WZG3J2MCOL

Background: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

Indication: For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).

Associated Conditions: Nausea and vomiting

Associated Therapies: -

Clinical Trials

Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients

Phase 2

Withdrawn

Conditions: Malignant Glioma

Interventions: Drug: Granisetron
Drug: Ondansetron

First Posted Date: 2013-09-30

Last Posted Date: 2014-09-22

Lead Sponsor: Duke University

Registration Number: NCT01952886

Locations: 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Palonosetron
Drug: Granisetron
Drug: Dexamethasone
Drug: Cisplatin

First Posted Date: 2013-07-29

Last Posted Date: 2015-12-04

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 92

Registration Number: NCT01909856

Locations: 🇨🇳
Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Phase 3

Completed

Conditions: Cancer of the Cervix

Interventions: Drug: Granisetron
Drug: Ondansetron
Behavioral: Questionnaires
Behavioral: Study Drug Diary

First Posted Date: 2012-02-22

Last Posted Date: 2021-06-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 76

Registration Number: NCT01536392

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Rolapitant
Drug: Granisetron
Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2011-12-28

Last Posted Date: 2016-03-02

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 1369

Registration Number: NCT01500226

Locations: 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Rolapitant
Drug: Granisetron
Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2011-12-28

Last Posted Date: 2016-03-02

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 555

Registration Number: NCT01500213

Locations: 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Rolapitant
Drug: Granisetron
Drug: dexamethasone
Drug: Placebo

First Posted Date: 2011-12-26

Last Posted Date: 2016-05-19

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 532

Registration Number: NCT01499849

Locations: 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States

Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc

Phase 4

Completed

Conditions: Prolonged QTc Interval

Interventions: Drug: Granisetron
Drug: Ondansetron

First Posted Date: 2011-05-11

Last Posted Date: 2011-05-11

Lead Sponsor: Tata Memorial Hospital

Target Recruit Count: 70

Registration Number: NCT01352130

Locations: 🇮🇳
Tata Memorial Hopsital, Mumbai, Maharashtra, India

Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

Phase 2

Terminated

Conditions: Nausea
Vomiting

Interventions: Drug: Aprepitant
Radiation: Palliative radiation therapy
Drug: Granisetron

First Posted Date: 2010-08-17

Last Posted Date: 2019-10-09

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 19

Registration Number: NCT01183481

Locations: 🇨🇦
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting (CINV)

Interventions: Drug: aprepitant
Drug: granisetron
Drug: dexamethasone

First Posted Date: 2009-08-06

Last Posted Date: 2017-06-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 421

Registration Number: NCT00952341

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: granisetron

First Posted Date: 2009-04-30

Last Posted Date: 2024-06-17

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT00890565

Locations: 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy